Please wait while your page loads ...

AAVLife start-up company to advance cardiac gene therapy in FA announces Series A funding

Bluebird Bio is a symbol, in a way, of the renaissance of gene therapy. The Cambridge, MA-based company raised $116 million in an IPO last year, and a number of startups pursuing gene therapy have cropped up since. So perhaps its no surprise that the field’s new entrant, AAVLife, comes from some of the same people that indirectly helped Bluebird get off the ground a few years ago.

Read More: BusinessWire: Xconomy


News & Press Archives

Privacy Policy      Service Terms      Contact      Charity Navigator